Component
Atropine, a muscarinic acetylcholine antagonist
Atropine, a muscarinic acetylcholine antagonist. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
At high levels of dihydrocapsaicin infusion above 2.0 mg/kg/h two single episodes of transient bradycardia and hypotension were observed in 33% of healthy rats, consistent with a TRPV1-agonist-induced Bezold-Jarisch reflex, whereas in resuscitated rats multiple episodes were observed in 100% of the rats at a dose of 0.65 mg/kg/h, and this effect could be completely blocked in the resuscitated rats by pre-treatment with the muscarinic acetylcholine antagonist atropine.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/dihydrocapsaicin-research/20807439.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "49bfe9de2b31cccc9afa70d322f9c96256968e48fdc033102fdb46394e617b0c", "start_char": 0, "end_char": 1709, "text_sha256": "49bfe9de2b31cccc9afa70d322f9c96256968e48fdc033102fdb46394e617b0c"}
- experimental_model
- Continuous intravenous infusion in healthy rats and in rats resuscitated from cardiac arrest, with atropine pre-treatment
- exposure
- Dihydrocapsaicin by continuous intravenous infusion at doses up to and beyond 2.0 mg/kg/h
- limitations
- The most important safety record in this collection, and the one whose population is the same population the therapy is aimed at. It is a rat study and the episodes are described rather than counted per animal.
- nutrient_topic
- Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. · Dihydrocapsaicin
- organism
- Rat
- plain_language
- After a cardiac arrest the same drug triggers dangerous slowing of the heart at a third of the dose, and atropine stops it.
- primary_references
- [dhc-p20807439] Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. Cardiovascular effects of dihydrocapsaicin. (2010). https://pubmed.ncbi.nlm.nih.gov/20807439/ DOI: 10.1186/1471-2261-10-39
- tissue_or_cell_type
- Cardiovascular system
- trigger_kind
- biomarker_context Imported condition classification; unverified.
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Continuous intravenous infusion in healthy rats and in rats resuscitated from cardiac arrest, with atropine pre-treatment · source_derived_draft · unverified_draft
### dhc-bezold-jarisch-susceptibility At high levels of dihydrocapsaicin infusion above 2.0 mg/kg/h two single episodes of transient bradycardia and hypotension were observed in 33% of healthy rats, consistent with a TRPV1-agonist-induced Bezold-Jarisch reflex, whereas in resuscitated rats multiple episodes were observed in 100% of the rats at a dose of 0.65 mg/kg/h, and this effect could be completely blocked in the resuscitated rats by pre-treatment with the muscarinic acetylcholine antagonist atropine. Condition category: biomarker_context nutrient_topic: Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. plain_language: After a cardiac arrest the same drug triggers dangerous slowing of the heart at a third of the dose, and atropine stops it. organism: Rat tissue_or_cell_type: Cardiovascular system experimental_model: Continuous intravenous infusion in healthy rats and in rats resuscitated from cardiac arrest, with atropine pre-treatment limitations: The most important safety record in this collection, and the one whose population is the same population the therapy is aimed at. It is a rat study and the episodes are described rather than counted per animal. exposure: Dihydrocapsaicin by continuous intravenous infusion at doses up to and beyond 2.0 mg/kg/h evidence_span: {"source_cache": "artifacts/dihydrocapsaicin-research/20807439.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "49bfe9de2b31cccc9afa70d322f9c96256968e48fdc033102fdb46394e617b0c", "start_char": 0, "end_char": 1709, "text_sha256": "49bfe9de2b31cccc9afa70d322f9c96256968e48fdc033102fdb46394e617b0c"} [dhc-p20807439] Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. Cardiovascular effects of dihydrocapsaicin. (2010). https://pubmed.ncbi.nlm.nih.gov/20807439/ DOI: 10.1186/1471-2261-10-39
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.